Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Gilead Sciences (NASDAQ:GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

"The first question he asked was did the team win," Mount Gilead head coach Jake Hayes said of his now four-time All-Ohioan ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

(This story was updated to accurately reflect the most current information.) OBETZ — Mount Gilead left nothing to chance this ...

OBETZ — Mount Gilead's boys cross country team has enjoyed a decade of dominance unlike any high school sports program in the Marion area. Saturday was another link in the chain when MG won the ...